AUSTRALIAN CANCER DRUG SECURES $730M DEAL

Written on the 1 February 2016

AUSTRALIAN CANCER DRUG SECURES $730M DEAL

A NEW cancer drug developed in Australia has been licensed to US pharmaceutical company Merck in a $730 million deal.

Merck will advance the drug to clinical trials, in a bid to commercialise the cancer and non-cancer blood disorder treatment worldwide.

The financial returns will be shared between the Cancer Therapeutics CRC and its research partners CSIRO, Monash University, Peter MacCallum Cancer Centre and the Walter and Eliza Hall Insititute, as well as the Wellcome Trust and Cancer Research Technology in the UK.

CSIRO research partner Dr Tom Peat says the drug is designed to inhibit the protein PRMT5, which is linked to a range of cancers including mantle cell lymphoma, lung cancer, breast cancer and colorectal cancer.

"Patients who have these types of cancers often have high levels of this protein, which is unfortunately also linked to poor survival rates," Dr Peat says.

"Using our recombinant protein production facilities, we were able to produce samples of these proteins, crystallise them for structure based drug design and support the consortium's pre-commercial investigations and trials.

"Access to high quality protein is absolutely critical in structural biology approaches to drug discovery, and CSIRO is pleased to be able to contribute this key capability."

He says the research consortium was able to develop a drug that binds to this protein, allowing it to target cancerous cells.

PRMT5 inhibitors also have the ability to switch on important genes in the development of blood, which could provide disease-modifying treatment options for patients with blood disorders like sickle cell disease and beta thalassemia.

"We're thrilled to be part of this development, which has the potential to make a real difference for patients here in Australia and around the globe," Dr Peat says.

 


Latest News

2017 BRISBANE TOP COMPANIES REVEALED

WHILE Queensland is regarded as an economy in transition with the winding down of the mining boom, the 2017 top 50...

2017 BRISBANE TOP COMPANIES 1-10

FROM insurance and banking to travel, gambling, retail, property and pizza, these "heavyweights" have ha...

2017 BRISBANE TOP COMPANIES 11-20

RETAIL, property, an airline, cars, real estate, software services, energy, agriculture, veterinary services bathr...

2017 BRISBANE TOP COMPANIES 21-30

JEWELLERS Michael Hill International listed in 2016 with a half-billion dollar market capitalisation and a new CEO...

Related News

FURNITURE DISRUPTOR SET TO SHARE HIS ONE OF A KIND BUSINESS MODEL

IT'S no secret that Australians love homemaking. Their ceaseless quest to create the perfect place to call hom...

WEEDING OUT THE ASX'S BURGEONING CANNABIS TREND: 8 COMPANIES TO WATCH

A NICHE is budding on the ASX in the form of medical cannabis, an industry which has been on the country's rad...

FRESH CLASS ACTION TO REVEAL ANOTHER SIDE OF SLATER AND GORDON DOWNFALL

ACA LAWYERS has issued a formal letter of demand to Andrew Grech (pictured), managing director of Slater and Gordo...

STARSHIPS WERE MEANT TO DELIVER DOMINO'S PIZZA

NICKI Minaj may have been off the mark when she declared 'starships were meant to fly'. However, she m...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter